NANETS Webinar Series:
Hereditary Syndromes with NETs: MEN1/2, VHL Pheochromocytoma /Paraganglioma

September 16, 2020 – September 16, 2021

Members login HERE to view the recording

Presenters:
Lauren Fishbein, MD, PhD, University of Colorado School of Medicine
Mark Lewis, MD, Intermountain Healthcare

Learning Objectives:

• Analyze the strengths and weaknesses of imaging modalities in identifying NETs
• Recognize the relationships between genetics, immunochemistry and NETs. Identify the goals and role of surgery in the treatment and management of NETs
• Examine the various symptom and medical management therapies of NETs
• Illustrate the challenges in diagnosing and managing NETs
• Apply a multidisciplinary approach to the management of NETs

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.

The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and 60% passing on MOC test, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NANETS Webinar Series:
Surgical Management of Pancreatic Neuroendocrine Tumors
in collaboration with the Society of Surgical Oncology 

June 18, 2020 – June 18, 2021, Part I and Part II

Members login here to view the recording

Presenters:
James Howe, MD, Carver College of Medicine, University of Iowa
Rodney Pommier, MD, Oregon Health & Science University Hospital

Moderators:
Jennifer Eads, MD, University of Pennsylvania (Part I)
Jennifer Chan, MD, Dana Farber Cancer Institute (Part II)

2 AMA PRA Category 1 Credits™, MOC and nursing continued education credits (must attend both webinars to obtain credits)

NANETS, in collaboration with the Society of Surgical Oncology (SSO), presents a two-part webinar on the published Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors (pNETs). 

Due to the rarity of these tumors, institutional experiences may be quite variable, and clinicians must rely upon their judgment and discussions in multidisciplinary tumor boards to best serve their patients. During this webinar, we will identify several areas related to the surgical management of patients with pNETs and will explore options for dealing with important clinical questions.

Click Here for the Consensus Paper 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.

The CMEsolutions designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NANETS in collaboration with the Society of Nuclear Medicine and Molecular Imaging presents:
PRRT: Background, Published Results, Patient Selection Details, Sequencing of Therapy, and Future Directions

July 23, 2020 – July 23, 2021

Members login here to view the recording

Presenters:
Lisa Bodei, MD, Memorial Sloan Kettering Cancer Center
Jonathan Strosberg, MD, Moffitt Cancer Center

Learning Objectives:

• Describe the regulatory considerations for the administration of 177Lu-DOTATATE
• Explain the adjunctive medication options and their appropriate utilization
• List the impact of PRRT on key endpoints including progression-free survival
• Identify potential risks of 177Lutetium-dotatate

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.

The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and 60% passing on MOC test, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.